Exploring the involvement of Adathoda vasica in hypoxia axis at the molecular level. Exploring the involvement of Adathoda vasica in hypoxia axis at the molecular level

The role of increased hypoxia has been identified for the many pathological features of SARS-CoV2, such as impaired immunity, airway hyper-inflammation, fibrosis, sepsis, and thrombosis. In this study, we tested the potential effect of Adhatoda Vasica (AV) aqueous extract, an ayurvedic anti-hypoxic, and anti-inflammatory medicine, on SARS-CoV2 infection using genome-wide expression approach. In this study, we did the genome-wide expression analysis of the lungs of mice treated with AV and compared them with transcriptome data of COVID19 patients. A meta-analysis of transcriptome profiles shows that AV may serve as a potential drug candidate to boost immune response and to prevent the transcriptional response elicited by SARS-CoV2 infection. Overall design: For the transcriptomic experiment, distilled water (vehicle) or AV administered to naïve BALB/c mice by oral gavage for four consecutive days. Lung total RNA was isolated on 4th day of experiment, and a microarray experiment performed using Affymetrix Gene Chip MTA 1.0 array according to manufacturer’s instruction. Gene expression analysis was performed using Affymetrix® Expression Console and functional analysis done by using the Enrichr tool.